Predictive Oncologyの空売り状況は、投資家がPredictive Oncologyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Predictive Oncology (NASDAQ:POAI) 株価情報, 空売り情報

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Inc

Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and maintains $22 price target.

News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Universal Technical, Maintains $22 Price Target

BWS Financial analyst Hamed Khorsand maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Sell and maintains $6 price target.

BWS Financial Maintains Sell on Sable Offshore, Maintains $6 Price Target

AdvisorShares, a pioneer in the cannabis investing space, offering global, domestic, and leveraged actively managed cannabis ETFs, has announced a reverse split of the issued and outstanding shares of the AdvisorShares MSOS Daily Leveraged ETF. The split will not change the total value of a shareholder's investment.
MSOX&nbsp; has a daily leveraged investment objective and is designed for experienced and sophisticated active day trading investors only. While the investment object is still designed to target two times the exposure the Fund will typically be in range above or below the two times leverage target. This ETF was built to provide more liquidity to these companies in this growing industry, but it's important for investors to remember this ETF is designed only for experienced and sophisticated active day trading investors. Please read the MSOX prospectus for all the risks associated with this ETF.
Effective before market open on November 26, 2024, the Fund will affect a reverse split of its issued and outstanding shares as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Fund Name</td>
<td colspan="1" rowspan="1">Reverse Split Ratio</td>
<td colspan="1" rowspan="1">Approximate decrease in total number of outstanding shares</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AdvisorShares MSOS Daily Leveraged ETF</td>
<td colspan="1" rowspan="1">1 for 20</td>
<td colspan="1" rowspan="1">95&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
Please note the CUSIP changes, effective November 26, 2024:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Fund Name</td>
<td colspan="1" rowspan="1">Ticker</td>
<td colspan="1" rowspan="1">Current CUSIP</td>
<td colspan="1" rowspan="1">New CUSIP</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AdvisorShares MSOS Daily Leveraged ETF</td>
<td colspan="1" rowspan="1">MSOX</td>
<td colspan="1" rowspan="1">00768Y313</td>
<td colspan="1" rowspan="1">00768Y289</td>
</tr>
</tbody>
</table>
</figure>
As a result of this reverse split, every twenty shares of the Fund will be exchanged for one share as indicated above. Accordingly, the total number of the issued and outstanding shares for the Fund will decrease by the approximate percentage indicated above. In addition, the per share net asset value (NAV) and next day's opening market price will be approximately twenty times higher for the Fund. Shares of the Fund will begin trading on the NYSE Arca on a split-adjusted basis on November 26, 2024.
A shareholder's investment value will not be affected by the reverse split. The table below illustrates the effect of a hypothetical one-for-twenty reverse split anticipated for the Fund, as applicable and described above:
&nbsp;1-for-20 Reverse Split
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Period</td>
<td colspan="1" rowspan="1"># of Shares Owned&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Hypothetical NAV &nbsp; &nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Total Market Value</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pre-Split</td>
<td colspan="1" rowspan="1">1,000</td>
<td colspan="1" rowspan="1">$10</td>
<td colspan="1" rowspan="1">$10,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Post-Split &nbsp; &nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">50</td>
<td colspan="1" rowspan="1">$200</td>
<td colspan="1" rowspan="1">$10,000</td>
</tr>
</tbody>
</table>
</figure>
The Trust's transfer agent will notify the Depository Trust Company (DTC) of the reverse split and instruct DTC to adjust each shareholder's investment(s) accordingly. DTC is the registered owner of the Fund's shares and maintains a record of the Fund's record owners.
Redemption of Fractional Shares and Tax Consequences for the Reverse Split
As a result of the reverse split, a shareholder of the Fund's shares potentially could hold a fractional share. However, fractional shares cannot trade on the NYSE Arca. Thus, the Fund will redeem for cash a shareholder's fractional shares at the Fund's split-adjusted NAV as of the Effective Date. A shareholder could recognize a gain or loss in connection with the redemption of the shareholder's fractional shares.
"Odd Lot" Unit
As a result of the reverse split, the Fund may have outstanding one aggregation of less than 5,000 shares to make a creation unit, or an "odd lot unit." Thus, the Fund will provide one authorized participant with a one-time opportunity to redeem the odd lot unit after the split-adjusted NAV is struck on November 26, 2024.

Stock Split

AdvisorShares Trust AdvisorShares MSOS 2x Daily ETF

MSOX

AdvisorShares Announces 1-For-20 Reverse Split Of ETF

Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Outperform and raises the price target from $65 to $90.

DAVE

Barrington Research Maintains Outperform on Dave, Raises Price Target to $90

CRH today announced the acquisition of Dutra Materials in San Rafael, California. This acquisition expands CRH's Americas Materials Solutions business and enhances its ability to provide integrated solutions to customers in northern California.
Dutra Materials complements CRH's Americas Materials Solutions business in the Western U.S., bringing additional strategic aggregate reserves and asphalt production capabilities to service the northern California construction market.

CRH Continues Expansion In California With Dutra Materials Acquisition; No Financial Terms Disclosed

In August 2024 we (&quot;Kaspi.kz&quot;) submitted a non-binding letter of interest to Uzbekistan&#39;s State Assets Management Agency (&quot;SAMA&quot;), indicating our interest in participating in the privatisation of the National Interbank Processing Center (&quot;Humo&quot;). At this time, we are not proceeding further in the process.
Uzbekistan&#39;s economy is growing fast and its government is pursuing an attractive reform agenda. Kaspi.kz&#39;s innovative digital products improve the everyday lives of consumers and merchants and we will continue to look for opportunities to play a part in Uzbekistan&#39;s exciting digital transformation.

Global

KSPI

In August 2024 Kaspi.kz Submitted A Non-Binding LOI To Uzbekistan's State Assets Management Agency, Indicating Our Interest In Participating In The Privatization Of The National Interbank Processing Center; At This Time, The Co Is Not Proceeding Further In The Process

Buybacks

Bunge Expands Share Repurchase Program By $500M, Increasing Total Authorization To $1.3B Following Sale Of Sugar And Bioenergy JV Interest; CEO Highlights Commitment To Capital Allocation

Macquarie analyst Paul Golding maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Outperform and raises the price target from $130 to $146.

Macquarie Maintains Outperform on Live Nation Entertainment, Raises Price Target to $146

AppTech Payments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $43.00 thousand in sales this quarter. This is a 69.29 percent decrease over sales of $140.00 thousand the same period last year.

Earnings

Earnings Misses

APCX

AppTech Payments Q3 EPS $(0.08) Misses $(0.06) Estimate, Sales $43.00K Down From $140.00K YoY

Cathie Wood, CEO of asset management giant Ark Invest, suggested that Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price could hit a base target of $650,000 by 2030, with an optimistic scenario reaching <a href="https://www.benzinga.com/money/bitcoin-price-prediction">as high as $1.5 million</a>. 
What Happened: Wood, a long-time Bitcoin proponent who first invested in the digital asset in 2015, attributes the surge in Bitcoin&#8217;s price to two primary factors: regulatory relief on the horizon and Bitcoin's growing distinction from other assets.
In an <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">interview</a> with CNBC on Friday, Wood said she sees institutional interest in Bitcoin intensifying, with asset allocators increasingly recognizing its unique behavior compared to traditional assets.
Ark Invest, which was the first public asset manager to gain Bitcoin exposure at $250 in 2015, maintains an optimistic outlook for the cryptocurrency's future.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41799045/ark-invests-cathie-wood-joins-call-for-strategic-bitcoin-reserve-gives-thumbs-up-to-cynthi">Ark Invest&#8217;s Cathie Wood Joins Call For Strategic Bitcoin Reserve, Gives Thumbs Up To Cynthia Lummis&#8217; Plan</a>
Wood's prediction ties into Ark Invest's broader outlook, which also includes optimism about the potential for the <a href="https://www.benzinga.com/24/11/41928272/cathie-woods-ark-invest-foresees-crypto-industry-boost-under-incoming-trump-administration">upcoming Donald Trump administration</a> to provide clearer regulations for the cryptocurrency industry in the United States.
With the end of current SEC Chair Gary Gensler&#8216;s term, the firm <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">anticipates</a> a more crypto-friendly SEC and a shift away from "regulation by enforcement," which could provide the regulatory clarity needed to spur further institutional investment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/41891628/ross-gerber-cathie-wood-or-gary-black-whose-funds-stack-up-against-sp-500s-gains-in-2024">Ross Gerber, Cathie Wood Or Gary Black? Whose Funds Stack Up Against S&amp;P 500&#8217;s Gains In 2024?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin To Hit Up To $1.5 Million By 2030, Says Cathie Wood

<a href="https://pr.report/4a65">Gladstone Commercial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) (the &quot;Company&quot;) announced that Terry Lee Brubaker will be retiring as Chief Operating Officer of the Company effective December 2, 2024. Mr. Brubaker is also retiring as director and executive officer of Gladstone Management Corporation, the Company&#39;s investment adviser, and as a member of the board of managers and an executive officer of Gladstone Administration, LLC, the Company&#39;s administrator, also effective December 2, 2024. Following Mr. Brubaker&#39;s departure, Michael LiCalsi, the Company&#39;s General Counsel and Secretary, who also serves as Gladstone Administration&#39;s President, General Counsel and Secretary, will assume certain additional operational responsibilities while Gladstone Management will conduct a national search for a Chief Investment Officer to fill Mr. Brubaker&#39;s investment committee responsibilities.

Management

GLAD

GOOD

Gladstone Announces Retirement Of COO Terry Lee Brubaker, Effective December 2, 2024; Michael LiCalsi, The Co's General Counsel And Secretary, Who Also Serves As Gladstone Administration's President, General Counsel And Secretary, Will Assume Certain Additional Operational Responsibilities

Insider Trades

Constellation Brands Director Richard Sands Sells 59,637 Shares At Average Price Of $240.38, Totaling $14.34M

LAND

Gladstone Land Announces Retirement Of COO Terry Lee Brubaker

<a href="https://www.globenewswire.com/Tracker?data=BVJO5xwsj0LDrAwUh3f-vBWd8O-_SqCpBG0OQjNTLTl8NV_twYqnXWKH3Tw11TbMrVsZnk_gKCIf66hPIR6PeWqOselKtKA0MlifgOq2mRRbk4p4SQOnMcFhljd8IDlL">Perspective Therapeutics, Inc.</a>&nbsp;("Perspective" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.
The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be presented by Richard L. Wahl, MD, (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) on Friday, November 22, 2024 at 9:05 am CT.&nbsp;&nbsp; Results of the study are also available as a poster (number C-37) at the NANETS symposium.

Biotech

General

CATX

Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4304665-1&amp;h=2441800747&amp;u=http%3A%2F%2Fwww.federalrealty.com%2F&amp;a=Federal+Realty+Investment+Trust">Federal Realty Investment Trust</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) announced today that Jeffrey S. Berkes, the Company's President and Chief Operating Officer, will be leaving the company effective December 31, 2024. Don Wood, Federal's Chief Executive Officer, commented, "Jeff has been my trusted partner and good friend here at Federal for the past 24 years and has been instrumental in growing the company and positioning the company as a leader in the industry. He's one of the finest professionals and human beings in our business. I'll surely miss working with him on a daily basis." Mr. Wood will reassume the additional position of President of the Company. The position of Chief Operating Officer will not be backfilled.
Wendy Seher, the Eastern Region President and Chief Operating Officer, a 22-year company veteran, and Jeff Kreshek, the Western Region President and Chief Operating Officer, a 13-year company veteran will continue in their senior operating roles at the Company and report directly to Mr. Wood.

Federal Realty Announces Jeffrey S. Berkes, The Company's President And Chief Operating Officer, Will Be Leaving The Company Effective December 31, 2024; Don Wood Will Reassume The Additional Position Of President Of The Company. The Position Of Chief Operating Officer Will Not Be Backfilled.

ADVM

Adverum Biotechnologies Schedules Webcast For November 18 To Present 52-Week LUNA Phase 2 And 4-Year OPTIC Clinical Data, Along With Key Pivotal Program Design

Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today provided an update regarding its previously discussed restatement process and subsequent SEC filings for the fiscal fourth quarter and year ended June 30, 2024, and the fiscal first quarter ended September 30, 2024.
On September 5, 2024, Flux announced that it had identified approximately $1.7 million of excess and obsolete inventory primarily related to product innovation and design of its products during a period of rapid growth over the last several years. A further detailed review of this and related items has resulted in estimated noncash inventory write-downs of approximately $4.4 million and related noncash warranty related items of approximately $0.5 million, totaling adjustments of approximately $4.9 million. This impact is not a one-time adjustment but impacting multiple quarters over multiple years. To properly reflect the obsolete inventory, the Company is currently in the process of restating previously issued financial statements for fiscal year 2023 and the interim periods of fiscal year 2024, which will be reflected in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024. The Flux team has completed its internal review of the restatements and 10-K and is working with its auditors to file them as soon as practicable, which reflects a large body of work over an extended period of time. Upon completion, Flux will work to complete the 10-Q filing for the quarter ending September 30, 2024.

FLUX

Flux Identifies $4.9M In Noncash Adjustments For Obsolete Inventory And Warranty Items, Plans To Restate FY23 And FY24 Financials; 10-K And 10-Q Filings Pending Auditor Review

Lakeside Holding Limited Q1 Total Revenues $4,148,476, Down 1.6% YoY, EPS $(0.18) vs $(0.05) YoY

<h3>Gainers</h3>
<ul>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares moved upwards by 23.0% to $6.89 during Friday's pre-market session. The market value of their outstanding shares is at $78.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares rose 19.37% to $0.96. The market value of their outstanding shares is at $9.4 million. </li>
<li>Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) stock rose 10.96% to $16.49. The company's market cap stands at $1.1 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares rose 7.62% to $0.43. The market value of their outstanding shares is at $27.7 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock increased by 7.09% to $0.9. The company's market cap stands at $103.9 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares increased by 6.98% to $16.89. The company's market cap stands at $4.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock decreased by 22.8% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares decreased by 17.15% to $0.02. The market value of their outstanding shares is at $10.2 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock declined by 12.0% to $1.1. The company's market cap stands at $22.2 million. </li>
<li>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) stock decreased by 8.67% to $2.74. The market value of their outstanding shares is at $159.6 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares decreased by 8.66% to $3.8. The company's market cap stands at $157.0 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock declined by 8.55% to $0.44. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

DBGI

DESP

DXLG

LGCY

MAMO

NRDY

SVMH

TCTM

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock increased by 71.0% to $0.32 during Friday's pre-market session. The company's market cap stands at $48.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares moved upwards by 18.58% to $0.58. The company's market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 18.02% to $0.77. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares fell 71.9% to $0.45 during Friday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 17.66% to $0.3. The company's market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 13.44% to $0.24. The company's market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CERO

CTCX

EYEN

GANX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

ISPC

TCBP

TFFP

TIVC

TKNO

12 Health Care Stocks Moving In Friday's Pre-Market Session

Here's the major earnings before the open tomorrow

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) just reported results for the second quarter of 2024.<ul><li>Predictive Oncology reported earnings per share of -68 cents.</li><li>The company reported revenue of $278,722.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/poai-stock-earnings-predictive-oncology-for-q2-of-2024/">POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024

Predictive Oncology GAAP EPS of -$0.68, revenue of $0.28M

Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript

Predictive Oncology files to sell 1.98M shares of common stock for holders

Predictive Oncology (POAI – Research Report) received a Buy rating and a $3.00 price target from H.C. Wainwright analyst Swayampakula Ramakanth tod...

H.C. Wainwright Initiates a Buy Rating on Predictive Oncology (POAI)

Predictive Oncology GAAP EPS of -$0.36 misses by $0.10, revenue of $0.35M in-line

Predictive Oncology Inc ( ($POAI) ) has released its Q3 earnings. Here is a breakdown of the information Predictive Oncology Inc presented to its i...

Predictive Oncology Inc. Reports Q3 2024 Earnings

Predictive Oncology (POAI – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The...

H.C. Wainwright downgrades Predictive Oncology (POAI) to a Hold

H.C. Wainwright downgraded Predictive Oncology (POAI) to Neutral from Buy without a price target after the company started working with a strategic...

Predictive Oncology downgraded to Neutral from Buy at H.C. Wainwright

ARCO

BCLI

BKKT

BLUE

CRMD

DOLE

EONGY

ESLT

FLNG

GLBE

HNHAF

IMNN

IPWR

ITRM

KMDA

KPLT

MDWD

MEDIF

MGIC

ONDS

OTLK

PFGC

POAI

PRPH

RSKD

SACH

SUNS

TCEHY

TSAT

VISL

VWDRY

WKHS

Health Care

Press Releases

Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

Comments

Predictive Oncology

空売り

Predictive Oncology (NASDAQ:POAI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル